Citius Oncology, Inc.(CTOR) - 2024 Q4 - Annual Report

Each of these risks could delay our clinical trials or the approval, if any, of our future product candidates by the FDA or any foreign regulatory agency or the commercialization of LYMPHIR and could result in higher costs or deprive us of potential product revenues. As a result, our business, financial condition, and results of operations might be materially harmed. 24 ● may identify deficiencies in the manufacturing processes or facilities of third-party manufacturers with which we enter into agreements f ...